Obesity and Erectile Dysfunction: Is Androgen Deficiency the Common Link?

Feeley, Robert J.; Traish, Abdulmaged M.

doi:10.1100/tsw.2009.79

Cited by 13 publications

(15 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results show that IgG could potentially be associated with ED risk, after adjusting for age. Meanwhile, in this analysis, a significant association between ED and metabolic syndrome, obesity, and so on was again identified [31]. In addition, seven genes [platelet-activating factor receptor (PTAFR), interleukin 27 (IL27), CD37 molecule (CD37), CD40 molecule (CD40), interleukin 7 receptor (IL7R), proteasome subunit, beta type, 9 (PSMB9), and chemokine (C-X-C motif) receptor 3 (CXCR3)] related to humoral immunity, which might be vital in inducing ED, were analyzed with SKAT.…”

Section: Resultsmentioning

confidence: 53%

“…This cross-sectional analysis of five immune elements (C3, C4, IgA, IgG, and IgM) and ED risk was conducted based on a population health survey. In the essential analysis, we found that age, obesity, drinking, educational status, and hyperglycemia could be associated significantly with ED risk, as shown in recent studies [31][32][33]. In order to discover the tendency of morbidity with age, we presented the relationship by intuitively drawing a curve chart.…”

Section: Immune Substances Associated With Edmentioning

confidence: 94%

See 1 more Smart Citation

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

et al. 2014

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a global disease affecting a large number of people. Some studies have found a relationship between low-grade inflammation and ED. We hypothesized that the immune system might play a key role in the outcome of ED. Five immune agents (C3, C4, IgA, IgM, and IgG) were collected based on the Fangchenggang Area Male Health and Examination Survey (FAMHES), using methods of a traditional cross-sectional analysis. Our results repeated the significant association between ED and metabolic syndrome, obesity, and so forth. However, there seemed to be no positive relation between the tested indexes and ED risk in the baseline analysis (C3: P = 0.737; C4: P = 0.274; IgA: P = 0.943; IgG: P = 0.069; IgM: P = 0.985). Then, after adjusting for age and multivariate covariates, a potentially significant association between ED and IgG was discovered (P = 0.025 and P = 0.034, respectively). Meanwhile, in order to describe the development of ED on a gene level, SNP–set kernel-machine association test (SKAT) was applied with the known humoral immune genes involved. The outcomes suggested that PTAFR (binary P value: 0.0096; continuous P value: 0.00869), IL27 (0.0029; 0.1954), CD37 (0.0248; 0.5196), CD40 (0.7146; 0.0413), IL7R (0.1223; 0.0222), PSMB9 (0.1237; 0.0212), and CXCR3 (0.0849; 0.0478) might be key genes in ED, especially IL27, when we restricted the family-wise error rate (FWER) to 0.5. Our study shows that IgG and seven genes (PTAFR, CD37, CD40, IL7R, PSMB9, CXCR3, and especially IL27) might be key factors in the pathogenesis of ED, which could pave the way for future gene and immune therapies.

show abstract

Section: Resultsmentioning

confidence: 53%

Section: Immune Substances Associated With Edmentioning

confidence: 94%

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Any factor that affects endothelial dysfunction and impairs endothelial nitric oxide release and the integrity of the vascular bed will certainly contribute to ED, as an erection depends on hemodynamics and vascular health. Obesity is furthermore associated with reduced plasma testosterone levels, thereby contributing to hypogonadism and ED [14,46]. In addition, there are reported relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type II diabetes mellitus.…”

Section: Physical Mechanismsmentioning

confidence: 99%

Obesity: modern man's fertility nemesis

Cabler

Agarwal²,

Flint³

et al. 2010

Asian J Androl

160

120

View full text Add to dashboard Cite

The obesity pandemic has grown to concerning proportions in recent years, not only in the Western World, but in developing countries as well. The corresponding decrease in male fertility and fecundity may be explained in parallel to obesity, and obesity should be considered as an etiology of male fertility. Studies show that obesity contributes to infertility by reducing semen quality, changing sperm proteomes, contributing to erectile dysfunction, and inducing other physical problems related to obesity. Mechanisms for explaining the effect of obesity on male infertility include abnormal reproductive hormone levels, an increased release of adipose-derived hormones and adipokines associated with obesity, and other physical problems including sleep apnea and increased scrotal temperatures. Recently, genetic factors and markers for an obesity-related infertility have been discovered and may explain the difference between fertile obese and infertile obese men. Treatments are available for not only infertility related to obesity, but also as a treatment for the other comorbidities arising from obesity. Natural weight loss, as well as bariatric surgery are options for obese patients and have shown promising results in restoring fertility and normal hormonal profiles. Therapeutic interventions including aromatase inhibitors, exogenous testosterone replacement therapy and maintenance and regulation of adipose-derived hormones, particularly leptin, may also be able to restore fertility in obese males. Because of the relative unawareness and lack of research in this area, controlled studies should be undertaken and more focus should be given to obesity as an etiolgy of male infertility.

show abstract

“…The risk of ED is even higher when diabetes is associated with obesity (Feeley and Traish, 2009). Diabetes and obesity are the most common risk factors for ED (Bacon et al, 2006;Giugliano et al, 2010) because of their deleterious effects on the vasculature (Tamler, 2009).…”

Section: Introductionmentioning

confidence: 99%

Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db^−/− Type II Diabetic and Obese Mice

Nunes

Teixeira

Priviero

et al. 2015

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Type 2 diabetes mellitus (DM2) and obesity are major risk factors for erectile dysfunction (ED). In diabetes, increased oxidative stress leads to decreased nitric oxide (NO) bioavailability, and diabetic patients appear to be less responsive to conventional therapy with phosphodiesterase type 5 inhibitors. We investigated whether the soluble guanylyl cyclase stimulator BAY 41-2272 (5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo [3,4-b] pyridine-3-yl]pyrimidin-4ylamine) is effective in improving impaired corpus cavernosum (CC) relaxation in obese DM2 mice by reducing oxidative stress. Adult db/db 2/2 mice or their lean db /1 littermates were used to assess vascular function, cGMP levels, antioxidant status, NADPH oxidase expression, and superoxide formation in the absence or presence of BAY 41-2272. Results showed that BAY 41-2272 (10 28 to 10 25 M) potently relaxed CC from db /1 or db/db 2/2 mice in a similar manner. BAY 41-2272 significantly enhanced both endotheliumdependent and nitrergic relaxation induced by electrical field stimulation (EFS), and improved the impaired relaxation to acetylcholine and EFS in the diabetic animals in a concentrationdependent manner (10 28 to 10 27 M). BAY 41-2272 increased cGMP levels and potentiated relaxation responses to exogenous NO in CC. Total antioxidant status was reduced in plasma and urine whereas expression of vascular NADPH oxidase subunits (gp91phox, p22phox, and p47phox) was increased in the CC of db/db 2/2 mice, suggesting a state of oxidative stress. These effects were prevented by BAY 41-2272 in a concentrationdependent manner. These results suggest that BAY 41-2272 improves CC relaxation in db/db 2/2 mice by increasing cGMP and augmenting antioxidant status, making this drug is a potential novel candidate to treat ED.

show abstract

Obesity and Erectile Dysfunction: Is Androgen Deficiency the Common Link?

Cited by 13 publications

References 82 publications

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

Obesity: modern man's fertility nemesis

Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db^−/− Type II Diabetic and Obese Mice

Contact Info

Product

Resources

About

Obesity and Erectile Dysfunction: Is Androgen Deficiency the Common Link?

Cited by 13 publications

References 82 publications

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

Immunization Associated with Erectile Dysfunction Based on Cross-Sectional and Genetic Analyses

Obesity: modern man's fertility nemesis

Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db−/− Type II Diabetic and Obese Mice

Contact Info

Product

Resources

About

Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db^−/− Type II Diabetic and Obese Mice